Sai Life Sciences is an Indian CRDMO providing discovery (CRO) and development plus commercial manufacturing (CDMO) for small molecules, and is now expanding into peptides, XDC conjugates, and formulations. In Q1 FY27, CDMO contributed 60% of revenue and CRO 40%, with total revenue of Rs 553 crore, up 12% year on year. The company works with 19 of the top 25 pharma companies, and returning customers accounted for over 90% of revenue in FY25 and FY26, a sign of deep repeat business. EBITDA margins have expanded from around 24% to 30% in 9M FY26, and management guides to sustain 28-30% long term, which is exceptional for this mix of services and manufacturing. The competitive structure is concentrated, with few players able to offer end-to-end small molecule CRDMO in India, and the dedicated FTE model is first-of-its-kind in the country.
The economics persist because of high switching costs built through customer qualification cycles, long-standing relationships, and the integrated FTE model that embeds the company into large pharma pipelines. The dedicated FTE teams have added 6 late-phase molecules in the last 15 months, with 5 of those arising from large pharma engagements, demonstrating how the model converts relationships into revenue. Repeat business over 90% of revenue in consecutive years confirms stickiness, while geopolitical shifts are pushing global pharma to diversify supply chains to India, and Sai Life Sciences is a qualified beneficiary. Scientific credibility is reinforced by a joint paper with AstraZeneca, peer-reviewed ADC bio-conjugation work, and an EcoVadis Platinum rating in 2026, placing it in the top 1% globally. These barriers are not easily replicated, as they require years of regulatory and quality validation from pharma clients.
The inflection is the capacity expansion now being commissioned. The first 225 KL production block at Bidar is on track for Q3 FY27, with a second 225 KL block to follow, bringing total capacity to approximately 1,150 KL by FY27, a roughly 70% increase. This capacity will convert to revenue in the second half of FY27 and into the following years. Additionally, a peptide GMP pilot facility is coming online shortly, with a commercial peptide facility targeted for operational status in 2028, and a formulation capability for early clinical supplies is about six months from readiness. The XDC Center of Excellence is nearly open. By mid-2028, the company should be generating revenue from small molecule manufacturing at a higher capacity, peptides at pilot and potentially early commercial scale, formulations for Phase 1/2 supply, and XDC discovery services. Management guides revenue growth of 15-20% over FY27-29 with EBITDA margins of 28-30%, and given that new discovery capacity sold out ahead of schedule, the revenue trajectory could exceed the top end if capacity fills as quickly.
Management has a consistent record of overdelivering. They guided 15-20% revenue CAGR over a three-to-five-year horizon but delivered 43% growth in 9M FY26. EBITDA margin guidance of 28-30% was achieved ahead of schedule at 30% in 9M FY26, and capex timelines have been met, with the 450 KL capacity addition confirmed on track. They also delivered exactly the 7 late-stage/commercial molecule additions promised for FY26. In the August 2026 call, they reaffirmed FY27 capex of Rs 1,100-1,300 crore, split 65% for CDMO and 35% for CRO, funded through internal accruals and debt. They expect H2 FY27 to be stronger than H1 as the new capacity goes live, and they have committed to transitioning at least two large pharma customers to integrated models this year and closing another large pharma FTE engagement by the end of Q2 FY27. This pattern of conservative guidance consistently exceeded supports the view that the financial targets are not aspirational but conservative.
The earnings path is visible: with 33 active commercial molecules and 14 late-phase molecules, plus new capacity ramping, the 15-20% revenue growth is well-supported. EBITDA margin should hold in the 28-30% band as operating leverage from existing costs and new capacity comes through. The single most important watchpoint is the absorption rate of the new 225 KL block in H2 FY27; if it fills as quickly as the discovery capacity did, the thesis strengthens materially. The risks are execution slippage of one or two months in capacity, lumpiness in CDMO quarterly shipments, and variable regulatory milestones for Phase 3 molecules. The tension in Q1 FY27, where CDMO grew only 6% while CRO grew 26%, is explained by shipment timing and the fact that new capacity is not yet online; it is operational, not structural. If the company fails to fill capacity within two quarters of commissioning, margins could compress from fixed costs, but management has signaled it can slow further capex, providing a downside buffer. Overall, the business 18-24 months from now should be a multi-modality CRDMO with roughly 70% more capacity, a sustained 28-30% EBITDA margin, and revenue growing at or above the guided range.
companyname: Sai Life Sciences Limited ticker: SAILIFE sector: Contract Research, Development and Manufacturing Organization (CRDMO) for small molecule new chemical entities Sai Life Sciences is a contract research, development, and manufacturing organization (CRDMO) focused exclusively on small molecule new chemical entities (NCEs). The company provides services across the entire drug lifecycle, from early discovery research through commercial manufacturing of active pharmaceutical ingredients...
Read the full report →capex, margin expansion
FY27-29 revenue growth guided at 15-20% with EBITDA margins of 28-30% over three years driven by integrated model and technology investments
Guidance maintainedoverdeliver
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Sai Life Sciences Limited and 4,900+ companies.
5-day free pass. No card required.